Your One-Stop-Shop for the Latest Advances in Oncolytic Virotherapy

2021 was a landmark year for clinical readouts within the oncolytic virotherapy field, and now OV developers are poised and ready at the cusp of something remarkable and this promising therapeutic is set to be a critical modality within cancer immunotherapy. With rapid advances in this compelling therapeutic, the Oncolytic Virotherapy Summit returns this December 2022 for its 7th edition.

As a leading industry forum, leading global biopharma will unite once again for three days dedicated to all things OV, as experts showcase clinical case studies and lead us through discussions to uncover the critical bottlenecks preventing widespread patient treatment with this promising therapeutic

 

What is in store for 2022?

    • Clinical Case Study presentations from global biopharma leaders, ensuring you remain ahead of the curve of the latest breakthroughs
    • Interactive discussions and conversations led by true thought leaders into OV selection and combination therapy considerations
    • Dedicated deep-dive workshops delving into the CMC, Quality Control, Manufacturing Policy and Regulatory Guidance
    • Showcasing expertise and insights from leading pharmaceutical experts from Amgen, Boehringer Ingelheim, Astellas and Bristol Myers Squibb as they navigate the world of licensing and partnering for OV’s

Companies Who Have Joined Us in the Past:

Takeda_logo_logotype
Pfizer_(2021)
AstraZeneca-Logo.wine
Bristol-Myers_Squibb_logo_(2020).svg
192-1921487_bluebird-bio-bluebird-bio-inc-logo
Genentech.svg
800px-AbbVie_logo.svg
Astellas_logo_logotype
1280px-Merck_Logo.svg
1200px-Boehringer_Ingelheim_Logo.svg
Bayer-Logo.wine
amgen
Janssen_Pharmaceuticals_logo.svg

Proud to Partner With: